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Lung cancer is the leading cause of cancer-related mortality in the world, with small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC) comprising the two major cell types. Although these cell types can be distinguished readily at the histological level,
knowledge of their underlying molecular differences is very limited. In this study, we compared 14 SCLC cell lines against 27 NSCLC
cell lines using an integrated array comparative genomic hybridisation and gene expression profiling approach to identify subtype-
specific disruptions. Using stringent criteria, we have identified 159 of the genes that are responsible for the different biology of these
cell types. Sorting of these genes by their biological functions revealed the differential disruption of key components involved in cell
cycle pathways. Our novel comparative combined genome and transcriptome analysis not only identified differentially altered genes,
but also revealed that certain shared pathways are preferentially disrupted at different steps in these cell types. Small cell lung cancer
exhibited increased expression of MRP5, activation of Wnt pathway inhibitors, and upregulation of p38 MAPK activating genes, while
NSCLC showed downregulation of CDKN2A, and upregulation of MAPK9 and EGFR. This information suggests that cell cycle
upregulation in SCLC and NSCLC occurs through drastically different mechanisms, highlighting the need for differential molecular
target selection in the treatment of these cancers.
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Lung cancer is the leading cause of cancer-related deaths
worldwide (Parkin et al, 2005). The disease is classified into
two major histological groups: small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC). Tobacco smoke is a major
etiological factor, especially in SCLC. Small cell lung cancer
comprises approximately 20% of all lung cancers and exhibits a
neuroendocrine phenotype while NSCLC lacks these features and
makes up the remaining 80% of cases. Small cell lung cancer
exhibits a more aggressive phenotype that inevitably reoccurs after
initial response to chemotherapy while the clinical outcome of
NSCLC is often hard to determine (Zakowski, 2003; Kurup and
Hanna, 2004; Stupp et al, 2004). Much of our current knowledge of
these subtypes has been derived from a canonical set of cell lines
derived from primary tumours (Phelps et al, 1996). These lines
have been particularly crucial in the understanding of SCLC for
which surgical resection is rarely performed (Rostad et al, 2004).
The variation in the development and progression of SCLC and
NSCLC may be a result of underlying differences in genetic alter-
ation. Although histological classification can separate these two
subtypes, previous studies using conventional genome scanning
techniques such as loss of heterozygosity analysis and comparative
genomic hybridisation (CGH) have shown that differences and
similarities in genetic aberration exist between SCLC and NSCLC
(Girard et al, 2000; Balsara and Testa, 2002). The limited
resolutions of these methods have hampered the ability to identify
discrete differences in genetic alterations, which are essential
to understanding the biochemical deregulation that lead to the
unique phenotypes of NSCLC and SCLC. Furthermore, the lack of
a well-defined progenitor cell type for SCLC has presented a major
challenge in establishing specific gene expression levels (Coe et al,
2006).
Owing to these limitations, it has become apparent that combin-
ing genomic and gene expression data will be essential for
identifying new tumour suppressors and oncogenes (Henderson
et al, 2005; Tonon et al, 2005). In addition, many genomewide
platforms have proved useful in defining recurrent regions of
alteration in lung cancer cells (Tonon et al, 2005; Zhao et al, 2005).
With the development of whole-genome tiling path array compa-
rative genomic hybridisation (aCGH), segmental copy number
changes unique to each cell type can be defined at high resolution
(Ishkanian et al, 2004). This technology allows the fine mapping of
genomic alteration boundaries to within a single bacterial artificial
chromosome (BAC) clone, identifying the precise genes potentially
affected by a copy number alteration (CNA). As alterations at the
DNA level are the initial events in cancer development, the gene
expression changes that occur as a result of these alterations will
be important in tumorigenesis.
To determine novel differences in CNA between the two lung
cancer cell types, we profiled the genomes of 41 lung cancer cell
lines (14 SCLC and 27 NSCLC) using the whole-genome tiling path
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sarray for CGH analysis. The integration of expression data for
these regions verified our findings and identified the gene
expression changes associated with CNA. Furthermore, comparing
expression and copy number levels between NSCLC and SCLC
without the requirement for normal expression levels circum-
vented a significant hurdle in the analysis of SCLC. Additionally,
difference-based analysis compensates for random cell culturing
artefacts, allowing insight into the clinical disease. Grouping the
differentially altered genes by biological function revealed cellular
pathways that may drive the pathological development of these cell
types. The discovery of these genes affected by phenotype-specific
CNA (PSCNA) may shed light on disease mechanisms and identify
novel molecular targets for therapeutics and diagnostics.
METHODS AND MATERIALS
DNA samples
The 41 lung cancer cell lines described were established at the
National Cancer Institute (NCI-H series) and at the Hamon Center
for Therapeutic Oncology Research, University of Texas South-
western Medical Center (HCC series) except for SW-900 and
SK-MES-1 (Fogh et al, 1977; Phelps et al, 1996). These cell lines
have been deposited for distribution in the American Type
Culture Collection (http://www.atcc.org). DNA was extracted from
27 NSCLC: 18 adenocarcinomas (H1395, H1648, H1819, H1993,
H2009, H2087, H2122, H2347, HCC78, HCC193, HCC366, HCC461,
HCC1195, HCC1833, HCC3255, HCC4006, HCC827 and HCC2279)
and 9 squamous cell carcinomas (H157, HCC15, HCC2450, HCC95,
H520, H226, SW 900, SK-MES-1 and H2170), and 14 SCLC cell
lines: nine classical (H187, H378, H889, H1607, H1672, H2107,
H2141, H2171, and HCC33) and five variant (H82, H289, H524,
H526, and H841). The identity of all 41 cell lines were verified by
fingerprinting using the Powerplex 1.2 system (Promega) which
contains nine polymorphic markers.
Tiling path array comparative genomic hybridisation
Segmental copy number status of the 41 lung cancer cell genomes
were deduced in array CGH experiments using sub-megabase
resolution tiling-set (SMRT) arrays. These arrays contain 97299
elements representing 32433 BAC-derived amplified fragment
pools spotted in triplicate on two aldehyde-coated glass slides
(Ishkanian et al, 2004; Watson et al, 2004). Array hybridisation
was performed as previously described (Coe et al, 2006; Garnis
et al, 2006). Briefly, 200–400ng of sample and a common reference
male genomic DNA (Novagen, Mississauga, ON, Canada) were
separately labelled by random priming in the presence of cyanine-
5 dCTP or cyanine-3 dCTP (PerkinElmer, Woodbridge, ON,
Canada), respectively. Labelled sample and reference DNA probes
were combined and purified using ProbeQuant Sephadex G-50
Columns (Amersham, Baie d’Urfe, PQ, Canada). The probe
mixture was precipitated in a solution containing 100mg Cot-1
DNA (Invitrogen, Burlington, ON, Canada) with 0.1  volume 3 M
sodium acetate and 2.5  volume 100% ethanol. The DNA pellet
was resuspended in 45ml of hybridisation solution containing 80%
DIG Easy hybridization buffer (Roche, Laval, PQ, Canada), 100mg
sheared herring sperm DNA (Sigma-Aldrich, Oakville, ON,
Canada), and 50mg yeast tRNA (Calbiochem, San Diego, CA,
USA) and denatured at 851C for 10min. Repetitive sequences were
blocked at 451C for 1h before hybridisation. Probes were then
added to array slides and placed in a pre-warmed hybridisation
chamber (Telechem, Sunnyvale, CA, USA). After hybridisation
for B40h at 451C, arrays were washed five times for 5min each
in 0.1  SSC, 0.1% SDS at room temperature in the dark with
agitation followed by five rinses in 0.1  SSC and dried by
centrifugation.
Imaging and data analysis
Images of the hybridised arrays were captured through cyanine-3
and cyanine-5 channels using a charge-coupled device (CCD)
scanner system (Applied Precision, Issaquah, WA, USA). Images
were then analysed using SoftWoRx Tracker analysis software
(Applied Precision, Issaquah, WA, USA). Spot signal ratio informa-
tion was mapped to genomic coordinates and median normalised.
Custom software called SeeGH was used to combine replicates and
visualise all data as log2 ratio plots in SeeGH karyograms and exclude
replicate data points which exceeded a standard deviation of 0.075
(Chi et al, 2004). In addition, genomic imbalances were identified
using aCGH-Smooth which uses a genetic local search algorithm to
identify breakpoints defining segmental DNA copy number changes
by using a maximum likelihood estimation to optimise breakpoint
location (Jong et al, 2004). As previously described, the Lambda and
breakpoint per chromosome settings were set to 6.75 and 100,
respectively (Jong et al, 2004; de Leeuw et al, 2004). The frequency of
alteration for each BAC was then individually determined for each
lung cancer cell type as described previously and plotted in SeeGH
Frequency Plot to visualise areas of recurrent deletion and
amplification (Coe et al, 2006). SeeGH software packages are
available upon request at: http://www.flintbox.ca/.
Statistical analysis of array comparative genomic
hybridisation alteration frequencies
Regions of differential copy number alteration between SCLC and
NSCLC genomes were identified using a stringent multistep filtering
process. The occurrence of copy number gain, loss, and retention at
each locus was compared between SCLC and NSCLC data sets using
Fishers exact test. Testing was performed using the R statistical
computing environment on a 3 2 contingency table with a P-value
threshold of 0.05. Loci for which the same cell type exhibited an
increased frequency of both gain and loss when compared to the
other were then excluded from these results in order to compensate
for regions demonstrating higher levels of genomic instability but
not true differential patterns of alteration. Finally, regions which
passed the first two criteria and demonstrated alteration frequen-
cies differing by at least 20% occurrence in either copy number loss
or gain were selected for further analysis.
Affymetrix gene expression analysis
Affymetrix HG-U133A and HG-U133B hybridisations were per-
formed as described in Henderson et al (2005). RNA expression
profiles were generated for 14 SCLC and 22 NSCLC cell lines, all of
which are present in the array CGH data set (H187, H378, H889,
H1607, H1672, H2107, H2141, H2171,H82, H289, H524, H526,
H841, H1395, H157, H1648, H1819, H1993, H2009, H2087, H2122,
H2347, H3255, HCC1195, HCC15, HCC1833, HCC193, HCC2279,
HCC2450, HCC366, HCC4006, HCC461, HCC78, HCC827, HCC95).
Absolute expression values were log-transformed and scaled to
a score between 0 and 100 using MAS 5.0 (Affymetrix, Santa
Clara, CA, USA), and only probe sets demonstrating a present or
marginal quality score in at least 50% of samples were considered
for further analysis. Gene expression data for SCLC and NSCLC
were then compared using the Mann–Whitney U test to identify
genes that differed in expression between the two cell types with a
P-value of at least 0.001. The resulting gene list was then filtered to
select only those genes for which the expression change matched
the direction predicted by the copy number analysis.
Real-time polymerase chain reaction
Real-time PCR validation of expression differences between
NSCLC and SCLC was performed on key genes identified through
combination of array CGH and Affymetrix gene expression
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sprofiling. Five micrograms of total RNA from each cell line
profiled by Affymetrix microarrays was converted to cDNA using
an ABI High Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA, USA). A measure of 100ng of cDNA was used for
each real-time PCR reaction. TaqMan (Applied Biosystems, Foster
City, CA, USA) gene expression assays: E2F2 (Hs00231667_m1),
SOX11 (Hs00846583_s1), MAP3K4 (Hs00245958_m1), HSPH1
(Hs00198379_m1), B-actin (Hs99999903_m1), 18S rRNA
(Hs99999901_s1) were performed using standard TaqMan reagents
and protocols on a Biorad I-cycler (Biorad, Hercules, CA, USA).
The DDCt method was used for expression quantification using the
average of the cycle thresholds for B-actin and 18s RNA to
normalize gene expression levels between samples. Expression
levels were compared between NSCLC and SCLC by a Mann–
Whiney U test as performed for the Affymetrix microarray data.
Principal components analysis
The 243 Affymetrix probe sets deregulated as a result of copy
number differences between SCLC and NSCLC were subjected to
principal component analysis. Analysis of the samples was
performed using the Statistics Toolbox (Version 5.1) of MATLAB
(Version 7.1) (The MathWorks Inc., Natick, MA, USA).
RESULTS AND DISCUSSION
Copy number analysis of lung cancer cell genomes
To facilitate the high-resolution search for novel genetic alterations
unique to each lung cancer cell type, we analysed 14 SCLC and 27
NSCLC cell lines with the SMRT CGH array. This array allows
the accurate assessment of segmental DNA copy number changes
at 32433 overlapping genomic loci in a single experiment,
producing copy number maps at 100kbp resolution across the
entire sequenced human genome (Ishkanian et al, 2004). After co-
hybridising differentially labelled sample DNA and a male genomic
DNA reference, fluorescence signal intensity ratios for each array
element were determined and displayed as log2 plots using
SeeGH software. Genetic alterations were identified in all cell lines
analysed. Figure 1 shows an example SeeGH karyogram for the
SCLC cell line H1672. Upon visual analysis of this profile, areas
of segmental gain and loss representing multiple levels of copy
number change can be observed. For example, the telomeric end of
chromosome arm 13q contains regions showing both single copy
gain and high-level amplification (Figure 1). In addition to the
multiple segmental alterations affecting the majority of chromo-
somes in this sample, discrete micro-amplifications and deletions
are also detected such as those highlighted on chromosome arms
18q and 2q, respectively. These minute changes may have been
missed by marker-based techniques and highlight the resolution
of the tiling path array. Array CGH karyograms for all the cell
lines are available online at http://www.bccrc.ca/cg/ArrayCGH_
Group.html.
Frequency analysis
Regions of chromosomal alteration, key to the development of
tumours, will be present in multiple samples. By aligning the
profiles of multiple genomes, patterns of gain and loss are revealed
and minimal regions that potentially contain tumour suppressor
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Figure 1 Sub-megabase resolution tiling-set (SMRT) array profile of the SCLC NCI-H1672 cells. Data is presented as a SeeGH karyogram to
demonstrate the resolving power of the SMRT technology. Each BAC clone is displayed as a vertical line representing its genomic coverage. The horizontal
shift of each line to the left or right of 0 represents the measured Log2 signal ratio from a competitive hybridisation with male genomic DNA. A decreased
ratio represents a loss of copy number compared to the reference sample while an increased ratio represents and increase in copy number. Multiple levels of
segmental copy number alteration as well as microalterations were readily detected (representative examples are highlighted in red and green). SeeGH
karyograms for all cell lines analysed are available at http://www.bccrc.ca/cg/ArrayCGH_Group.html.
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sgenes and oncogenes can be identified. Thus, after generating
the whole-genome tiling path array CGH profiles of the lung
cancer genomes, we then proceeded to identify recurrent regions
of aberration within each cell type. To do this we employed a
computer algorithm, aCGH-Smooth, to aid in the automated
detection of regions of chromosomal gain and loss (Jong et al,
2004). The frequency of alteration of each genomic locus assayed
was then calculated individually for the cell types and plotted using
SeeGH Frequency Plot software as previously described (Coe et al,
2006). The data used to generate the frequency diagrams is present
in Supplementary Material. The frequency plots and a detailed
description of the recurrent regions of alteration specific to these
SCLC and NSCLC cell lines have been reported (Coe et al, 2006;
Garnis et al, 2006).
Genetic alterations unique to each cell type may contain genes
responsible for the difference in disease development and clinical
behaviour. To identify these regions, we overlaid the frequency plot
diagrams of the SCLC and NSCLC samples and then compared the
alteration frequencies in the two groups to determine regions that
were statistically different by a 3 2 Fishers exact test and exclusion
of regions which demonstrated increased gain and loss frequency
for a single cell type (Figure 2). In this figure, areas indicated in
green are more frequently altered in SCLC while those in red are
more frequently altered in NSCLC. The yellow represents areas of
overlap between the two frequency plots. Regions shaded in blue
are those determined to be differentially altered in the cell types.
Regions of similarity
Among the regions that were not statistically different, there were
some striking similarities (Figure 2). Consistent with previous
reports, chromosome 3p loss was present in approximately 75% of
both the NSCLC and SCLC samples (Balsara and Testa, 2002). This
is consistent with previous results demonstrating that the deletion
of putative tumour suppressor genes (TSGs), such as FHIT and
RASSF1, contained on this chromosome arm are important genetic
events in the development of lung cancers (Zabarovsky et al, 2002).
Likewise, copy number loss of chromosome arm 4q was evident in
B50% of samples in each cell type mirroring results observed
using conventional CGH (Petersen et al, 1997a,b)(Figure 2).
The NSCLC and SCLC cell lines also showed similar frequency
of copy number gain on chromosomes arm 5p as well as at
chromosome bands 7p22.3 and 11q13.1–11q14.1. Over-represen-
tation of the entire 5p arm was a recurrent event in both cell types
with the telomeric end of 5p15.33 showing the greatest amount of
change. This region contains the telomerase reverse transcriptase
(hTERT) gene which has been implicated in cell immortalisation in
numerous cancers (Tomoda et al, 2002; Ramirez et al, 2004). Gain
of the 11q13.1–11q14.1 region was present in 450% of the lung
cancer cell lines with the highest degree of concordance at 11q13.3
(Figure 2). Cyclin D1, which is involved in the inactivation of the
retinoblastoma protein and progression of the cell cycle through
the G1–S phase, is located at this loci (Muller et al, 1994). This
finding supports the theory that amplification of this gene is
an important event in tumorigenesis (Fu et al, 2004). The gain
of 7p22 was particularly interesting as it was the most common
copy number aberration in both cell types. The minimal common
alteration within this amplified area in the SCLC cell lines contains
only one gene, MAD1L1 (validated by Coe et al, 2006). Although
this is a checkpoint gene involved in growth inhibition, its gain
has been reported in other cancers (Jin et al, 1999; Tsukasaki
et al, 2001; de Leeuw et al, 2004). The high frequency of MAD1L1
Alteration frequency
Chr. 1 Chr. 2 Chr. 3 Chr. 4 Chr. 5 Chr. 6 Chr. 7 Chr. 8
Chr. 16 Chr. 15 Chr. 14 Chr. 13 Chr. 12 Chr. 11 Chr. 10
Chr. 17 Chr. 18 Chr. 19 Chr. 20 Chr. 21 Chr. 22
Sample key
SCLC NSCLC
Chr. 9
–100% +100%
Figure 2 Copy number alterations in SCLC and NSCLC. Alteration frequencies for SCLC (green) and NSCLC (red) are displayed as bar plots adjacent to
chromosomal ideograms. Bars extending to the right of each chromosome represent the frequency of copy number gain; conversely, bars extending to the
left represent the frequency of copy number loss. Yellow regions represent overlapping portions of the SCLC and NSCLC alteration frequencies. Blue bars
indicate regions demonstrating significantly different alteration frequencies. Vertical brown lines on the left of each frequency diagram indicate regions
selected for further analysis.
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Figure 3 Differential expression as a result of copy number alteration. Affymetrix log-transformed absolute expression data for the 243 probe sets exhibiting strong differential expression between SCLC
and NSCLC associated with copy number differences are displayed. High-level expression is indicated by white/yellow while blue/black indicates progressively lower levels of expression. The SCLC samples
are indicated by green highlighting of each column, while NSCLC samples are indicated by red highlighting. Each probe set is sorted according to its chromosomal position and cell lines are sorted
alphabetically, according to their cell type. Probe set with annotated gene IDs are labelled with their RefSeq name while probe sets with less reliable mapping are indicated by their probe ID alone. Average
expression values were calculated for genes with multiple Affymetrix probe sets, which passed the filtering conditions. These are indicated in blue text (The number of probe sets averaged is indicated in
brackets). The primary genomic alteration observed for both SCLC and NSCLC are indicated to the right of each set of expression values (G¼‘gain’, L¼‘loss’, no value¼‘gained and lost’ or ‘no change’).
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Genetics and Genomicsamplification in the NSCLC samples as well suggests that this
gene may play an essential role in the development of lung cancers
(Garnis et al, 2006).
It is noteworthy that a subset of the genomic similarities
between the SCLC and NSCLC cell lines could be the result of
adaptation to culturing conditions. Owing to this, the greatest
insight into the biology of the clinical disease will be attainable
through analysis of differences (rather than their similarities) in
genomic alterations and gene regulation.
Regions of difference
Through our analysis, numerous regions throughout the genome
were determined to be differentially altered between the SCLC and
NSCLC samples. This difference-based approach compensates for
random cell culturing artefacts and should identify the regions
most strongly linked to clinical disease. These regions ranged in
size from whole chromosomes (chromosome 21) to discrete peaks,
kilobases in size (3q27.1). Using our stringent, multistep criteria
(Fisher’s exact test followed by additional thresholding), we detec-
ted several regions that differed strongly in their alteration status
between the cell types, we refer to these as phenotype-specific copy
number alterations (PSCNAs). These included 1p36.33–1p34.2,
100
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Figure 4 Contribution of copy number-induced gene expression
differences to the SCLC and NSCLC phenotypes. Principal components
analysis was performed utilising all 243 Affymetrix probe sets demonstrat-
ing expression differences as a result of copy number alterations. The SCLC
samples are indicated by solid circles, while the NSCLC samples are
indicated by open circles. Strong separation of the SCLC and NSCLC cell
lines along principal component 1 demonstrates the contribution of these
genes to the differential phenotypes.
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s2p25.3–2p24.3, 3q26.33–3q28, 5q34–5q35.3, 6q24.2–6q27, 7p13–
7p11.2, 8q21.2–8q22.3, 8q24.11–8q24.23, 9p22.3–9p21.1, 10q11.21–
10q11.23, 12q24.31–12q24.33, 13q12.11–13q13.1, 13q32.2–13q34,
17q11.2, 18p11.23–18p11.21, 18q21.1–18q22.2, 19p13.2–19p12 and
21q11.2–21q22.3.
Some of these regions showed completely opposite patterns
of alteration in the different cell types. 21q11.2–21q22.3 was a
striking example as it is very frequently gained in SCLC but deleted
in the NSCLC cases. Other regions were altered (gained or lost) in
one cell type but remained almost unchanged in the other, for
example the 8q21.2–8q22.3 locus that is commonly gained only
in NSCLC. In addition, we observed chromosome segments altered
in the same manner in both cell types, but to a greater extent in
one over the other. 7p13–7p11.2 displays this characteristic as it is
gained in B50% of the SCLC cell lines and B80% of the NSCLC
samples.
The genes within these major regions of disparity may be
responsible for the difference in disease development. However,
not all genes contained in these regions will be differentially
expressed as a consequence of the PSCNAs. To validate these
CNAs and identify genes within these regions responsible for the
different cell phenotypes, gene expression analyses were required.
Identification of genes differentially expressed between
small cell lung cancer and non-small cell lung cancer
caused by phenotype-specific copy number alteration
Validation of the genomic differences identified between SCLC
and NSCLC cell lines was performed by assessment of their impact
at the gene expression level. This is achieved by integrating
Affymetrix expression profiling data with the array CGH data
presented above. Owing to the lack of a defined normal cell type
for SCLC, the definition of specific over and underexpression of
genes is difficult to establish. To circumvent this limitation we
compared Affymetrix absolute expression values for both the
NSCLC and SCLC samples to determine differential expression
between the cell types.
Genes contained within the regions of peak genomic copy
number difference were selected from the expression data and
filtered to identify only those genes which exhibited expression
differences between the two cell types presumably as a result of
the copy number differences (Affymetrix gene expression data for
the regions of genomic difference is available in Supplemental
Material). A strict Mann–Whitney U-test P-value threshold of
0.001 as well as a requirement for expression differences to match
the direction of copy number difference (i.e. increased expression
in samples with a higher frequency of copy number gain and
reduced expression in cells with a high frequency of copy number
loss), identified 243 of 5185 analysed Affymetrix probe sets,
corresponding to 159 unique RefSeq genes, as being differentially
regulated between SCLC and NSCLC (Figure 3) (Also presented in
Supplementary Material). The nature of our approach filters out
genes with differential expression due to factors other than copy
number such as methylation and the mutation and up/down-
regulation of upstream genes. As such, these 159 genes most likely
represent the expression differences resulting from SCLC and
NSCLC PSCNAs. This hypothesis is supported by principal
components analysis, which demonstrated the strong contribution
of the 159 genes to the differential phenotypes of SCLC and NSCLC
(Figure 4).
Analysis of the 159 genes not only revealed several expected
findings such as an increased level of EGFR expression in NSCLC,
but identified novel differentially expressed genes such as MRP5
(Amann et al, 2005; Ritter et al, 2005) which exhibited increased
Table 1 Differential deregulation of genes in key biochemical pathways between NSCLC and SCLC
Gene symbol Gene name Locus Regulation
STMN1 Stathmin 1 1p36.11 SCLC +
E2F2 E2F transcription factor 2 1p36.12 SCLC +
ZNF151 (MIZ1) Zinc-finger protein 151 (Myc-interacting zinc-finger protein) 1p36.13 SCLC +
PRDM2 (RIZ1) PR domain-containing protein 3 (Rb protein-binding zinc-finger protein) 1p36.21 SCLC +
ID2 Inhibitor of DNA binding 2 2p25.1 SCLC +
SOX11 SRY-related HMG-Box gene 11 2p25.2 SCLC +
MAPK9 (JNK2) Mitogen-activated protein kinase 9 (C-JUN kinase 2) 5q35.3 NSCLC +
MAP3K4 Mitogen-activated protein kinase kinase kinase 4 6q26 SCLC +
EGFR Epidermal growth factor receptor 7p11.2 NSCLC +
CDKN2A (p16INK4A) Cyclin-dependent kinase inhibitor 2A 9p21.3 NSCLC -
KNTC1 Kinetochore-associated protein 1 12q24.31 SCLC +
HMGB1 High mobility group Box 1 (Amphoterin) 13q12.3 NSCLC  
HSPH1 Heat shock 105kD 13q12.3 NSCLC  
ING1 (p33ING1) Inhibitor of growth family member 1 13q34 SCLC +
JJAZ1 (SUZ12) Joined to JAZF1 (Suppressor of ZESTE 12) 17q11.2 SCLC +
NLK Nemo-like kinase 17q11.2 SCLC +
SMAD4 Mothers against decapentaplegic homolog 4 18q21.1 SCLC +
CCDC5 Coiled-coil domain containing 5 18q21.1 SCLC +
TCF4 Transcription factor 4 18q21.2 SCLC +
JUNB Oncogene jun-B 19p13.13 SCLC +
TIAM1 T-cell lymphoma invasion and metastasis 1 21q22.11 SCLC +
DSCAM Down’s syndrome cell adhesion molecule 21q22.2 SCLC +
SCLC¼small cell lung cancer; NSCLC¼non-small cell lung cancer; +¼increased expression in the indicated cell type;  ¼decreased expression in the indicated cell type.
Figure 5 Differential targets of copy number-induced expression changes in key biochemical pathways between SCLC and NSCLC. Strong PSCNA-
induced expression differences were identified between SCLC and NSCLC in several key pro-proliferate pathways. Genes with increased expression in
SCLC when compared to NSCLC are indicated in green, while genes with increased expression in NSCLC are indicated in red. Genes exhibiting a tumour
suppressor like pattern of reduced expression as a result of frequent copy number loss in NSCLC are indicated in yellow. Genes added to the pathways
for context but for which no expression differences were detected, are indicated in grey. Critical pathway nodes validated by real-time PCR are indicated
with a *.
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sexpression in SCLC. This gene encodes an ABC transporter known
to clear various chemotherapeutics from the cytoplasm and
increased expression in lung cancer has been associated with
exposure to platinum drugs (Oguri et al, 2000). Furthermore,
another study has correlated MRP5 expression to cisplatin
chemoresistant lung cancer cell lines (Weaver et al, 2005). This
result suggests a possible mechanism of enhanced chemo-
therapeutic resistance for the SCLC cells.
Biological pathways differentially altered in small cell lung
cancer and non-small cell lung cancer
Further analysis of the differentially expressed genes revealed that
a strikingly high number of genes are present in a small set of
interconnected pathways. The presence of multiple genes affected
by PSCNA in the MAPK and EGFR pathways lead us to examine
the known interactors for each of these genes to elucidate a
biochemical differentiation between SCLC and NSCLC cells.
The results of this analysis are displayed in Figure 5. Twenty-two
of the genes differentially altered between SCLC and NSCLC
are components of the cell cycle, EGFR, MAPK, p38MAPK, and
WNT pathways (Table 1). Four genes (E2F2, SOX11, MAP3K4, and
HSPH1), which represent critical nodes in these pathways, were
further examined by real-time PCR validating differential expres-
sion between SCLC and NSCLC. Pathway information was derived
from the Signal Transduction Knowledge Environment (stke.
sciencemag.org), the Kyoto Encyclopedia of Genes and Genomes
(http://www.genome.jp/kegg), and the following references:
Ishitani et al, 1999; Lundberg and Weinberg, 1999; Sakamuro
and Prendergast, 1999; Taguchi et al, 2000; Shaulian and Karin,
2001; Zebedee and Hara, 2001; Hyodo-Miura et al, 2002; Schneider
et al, 2002; Yamagishi et al, 2002; Bracken et al, 2003; Polager and
Ginsberg, 2003; Williams et al, 2003; Wu et al, 2003; Campos et al,
2004; Einarson et al, 2004; Li and Guan, 2004; Rubin and Atweh,
2004; Wada and Penninger, 2004; Sasahira et al, 2005. Of particular
interest was a strong increase in the expression of WNT inhibitors
in SCLC cells, namely NLK, SOX11, and TCF4. This remarkable
result demonstrates that the WNT pathway may not be a signi-
ficant player in SCLC.
Additionally we detected a strong difference in the regulatory
components of the p38MAPK pathway with the reduced expression
of two p38 MAPK activating genes in NSCLC (HMGB1, HSPH1)
and contrasting overexpression of two p38 MAPK activating genes
in SCLC (MAP3K4, DSCAM). We also observed strong PSCNA-
related overexpression of several members of the MAPK and cell
cycle pathways in both cell types, albeit through different
components. In the NSCLC samples, we observed segmental loss
and downregulation of the cell cycle inhibitor CDKN2A as well as
copy number gain and upregulation of MAPK9 and EGFR when
compared to SCLC. In contrast, the SCLC cells demonstrate
comparatively higher expression of many pro-proliferative genes;
these are detailed in Figure 5. Interestingly, several genes with
cell cycle inhibitory functions exhibited PSCNA-induced over-
expression in SCLC. Owing to likely antagonism of these genes by
the many upregulated cell cycle-activating genes, it is possible that
they perform a novel role secondary to their primary functions in
cell cycle regulation. These differential patterns of oncogenic
disruption to cell cycle pathways highlight the need to examine
cell type-specific targets for therapeutic pathway intervention.
For example, although a recent study has shown that EGFR is
expressed at low levels in SCLC, (Tanno et al, 2004) our results
indicate that the pathway is being activated by overexpression of
multiple downstream components, potentially bypassing benefits
that may be derived from EGFR-targeted therapy.
CONCLUSIONS
Whole-genome array CGH in conjunction with global expression
profiling analysis has allowed the identification of genes deregu-
lated as a result of PSCNA between SCLC and NSCLC cells. The 159
genes revealed as having strongly divergent expression patterns as
a result of copy number alterations identified a remarkable pattern
of gene deregulation in several key biological pathways. Cell
cycle upregulation in SCLC and NSCLC occurs through drasti-
cally different targets, suggesting a need for differential therapeutic
target selection. Additionally the WNT pathway, which has
recently received much attention for its involvement in NSCLC,
appears to be strongly downregulated in SCLC through PSCNA-
induced overexpression of inhibitory genes. This work represents
the first comprehensive search for the causative genetic alterations
distinguishing SCLC and NSCLC by integrating whole-genome
expression and copy number analysis platforms.
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